{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:39:07Z","timestamp":1792723147702,"version":"4.5.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007063","name":"University of Delhi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.biopha.2020.110891","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T18:04:49Z","timestamp":1603130689000},"page":"110891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Decoding the silent walk of COVID-19: Halting its spread using old bullets"],"prefix":"10.1016","volume":"133","author":[{"given":"Mukesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitender","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupinder Kaur","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi Bala","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Katyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110891_bib0005","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.biopha.2020.110891_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110891_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","article-title":"Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins","volume":"583","author":"Lam","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110891_bib0020","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1001\/jama.294.18.2291","article-title":"Bats may be SARS reservoir","volume":"294","author":"Hampton","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110891_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.biopha.2020.110891_bib0030","series-title":"Bats and Coronaviruses, Viruses11","first-page":"41","author":"Banerjee","year":"2019"},{"key":"10.1016\/j.biopha.2020.110891_bib0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110891_bib0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110891_bib0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jmv.25699","article-title":"The first two cases of 2019-CoV in Italy: Where they come from?","volume":"92","author":"Giovanetti","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0050","doi-asserted-by":"crossref","first-page":"104212","DOI":"10.1016\/j.meegid.2020.104212","article-title":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event","volume":"79","author":"Paraskevis","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.biopha.2020.110891_bib0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110891_bib0060","first-page":"16","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","volume":"382","author":"Doremalen","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0065","doi-asserted-by":"crossref","first-page":"106054","DOI":"10.1016\/j.ijantimicag.2020.106054","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies","volume":"56","author":"Sharma","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110891_bib0070","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.12998\/wjcc.v8.i8.1391","article-title":"Stability and infectivity of coronaviruses in inanimate environments","volume":"8","author":"Ren","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.biopha.2020.110891_bib0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of 2019-nCoV","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2020.110891_bib0080","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nature Microbiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0085","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for recognition of SARS-COV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2020.110891_bib0090","first-page":"1","article-title":"Structure, function, and antigenicity of the SARSCoV-2 spike glycoprotein","volume":"180","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2020.110891_bib0095","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI113240","article-title":"Fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas","volume":"80","author":"Schalken","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.110891_bib0100","doi-asserted-by":"crossref","first-page":"22075","DOI":"10.1016\/S0021-9258(18)45669-4","article-title":"Structure and expression of mouse furin, a yeast Kex2-related protease. Lack of processing of coexpressed prorenin in GH4C1 cells","volume":"265","author":"Hatsuzawa","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110891_bib0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0110","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0115","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1128\/JVI.00415-08","article-title":"Cathepsin L functionally cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I fusion protein upstream of rather than adjacent to the fusion peptide","volume":"82","author":"Bosch","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0120","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","article-title":"Single-stranded siRNAs activate RNAi in animals","volume":"150","author":"Lima","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2020.110891_bib0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fgene.2012.00101","article-title":"Thermodynamic control of small RNA-mediated gene silencing","volume":"3","author":"Ui-Tei","year":"2012","journal-title":"Frontiers Genet."},{"key":"10.1016\/j.biopha.2020.110891_bib0130","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1128\/JVI.01331-15","article-title":"The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells","volume":"89","author":"Cui","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1099\/0022-1317-83-3-595","article-title":"Conservation of substrate specificities among coronavirus main proteases","volume":"83","author":"Hegyi","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0140","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1128\/JVI.78.18.9977-9986.2004","article-title":"Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins","volume":"78","author":"Prentice","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0145","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0150","first-page":"E3900","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","author":"Subissi","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.biopha.2020.110891_bib0155","doi-asserted-by":"crossref","first-page":"e36521","DOI":"10.1371\/journal.pone.0036521","article-title":"Mechanism of nucleic acid unwinding by SARS-CoV helicase","volume":"7","author":"Adedeji","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110891_bib0160","doi-asserted-by":"crossref","first-page":"25783","DOI":"10.1074\/jbc.M114.577353","article-title":"CoronavirusNsp10, a critical Co-factor for activation of multiple replicative enzymes","volume":"289","author":"Bouvet","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110891_bib0165","doi-asserted-by":"crossref","first-page":"13399","DOI":"10.1128\/JVI.79.21.13399-13411.2005","article-title":"The nsp2 replicase proteins of murine hepatitis virus and Severe Acute Respiratory Syndrome Coronavirus are dispensable for viral replication","volume":"79","author":"Graham","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0170","doi-asserted-by":"crossref","first-page":"11620","DOI":"10.1128\/JVI.00702-07","article-title":"Severe Acute Respiratory Syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain","volume":"81","author":"Wathelet","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0175","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/cr.2012.64","article-title":"Polarized sorting and trafficking in epithelial cells","volume":"22","author":"Cao","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.virol.2016.07.022","article-title":"Tubulins interact with porcine and human S proteins of the genus Alphacoronavirusand support successful assembly and release of infectious viral particles","volume":"497","author":"Rudiger","year":"2016","journal-title":"Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0185","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.03999-14","article-title":"Inhibition of endoplasmic reticulum-resident glucosidases impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2","volume":"59","author":"Zhao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2020.110891_bib0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11262-010-0544-x","article-title":"SARS-CoV nucleocapsid protein antagonizes IFN-bresponse by targeting initial step of IFN-binduction pathway, and its C-terminal region is critical for the antagonism","volume":"42","author":"Lu","year":"2011","journal-title":"Virus Genes"},{"key":"10.1016\/j.biopha.2020.110891_bib0195","doi-asserted-by":"crossref","first-page":"e02143","DOI":"10.1128\/JVI.02143-16","article-title":"The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-Mediated RIG-I ubiquitination","volume":"91","author":"Hu","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11596-020-2172-6","article-title":"Clinical characteristics of children with coronavirus disease 2019 in Hubei, China","volume":"40","author":"Zheng","year":"2020","journal-title":"Current Med. Sci."},{"key":"10.1016\/j.biopha.2020.110891_bib0205","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1128\/jvi.68.10.6523-6534.1994","article-title":"Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding","volume":"68","author":"Klumperman","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0210","series-title":"Nidoviruses.","first-page":"179","article-title":"Coronavirus structural proteins and virus assembly","author":"Hogue","year":"2008"},{"key":"10.1016\/j.biopha.2020.110891_bib0215","doi-asserted-by":"crossref","first-page":"12557","DOI":"10.1128\/JVI.78.22.12557-12565.2004","article-title":"Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production","author":"Huang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0220","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biocel.2005.10.022","article-title":"Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction","volume":"38","author":"Luo","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2020.110891_bib0225","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1529\/biophysj.105.080119","article-title":"Model of a putative pore: the pentameric alpha-helical bundle of SARS coronavirus E protein in lipid bilayers","volume":"91","author":"Torres","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.biopha.2020.110891_bib0230","doi-asserted-by":"crossref","first-page":"L39","DOI":"10.1529\/biophysj.108.133041","article-title":"Structural flexibility of the pentameric SARS coronavirus envelopeprotein ion channel","volume":"95","author":"Parthasarathy","year":"2008","journal-title":"Biophys. J."},{"key":"10.1016\/j.biopha.2020.110891_bib0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.virol.2015.08.010","article-title":"Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome","volume":"485","author":"Nieto-Torres","year":"2015","journal-title":"Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0240","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JVI.02576-13","article-title":"Inhibition of NF-kappaB mediated inflammation in severe acute respiratory syndome coronavirus-infected mice increases survival","volume":"88","author":"DeDiego","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0245","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1128\/JVI.00873-09","article-title":"Low endocytic pH and capsid protein autocleavage are critical components of flock house virus cell entry","volume":"83","author":"Odegard","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0250","article-title":"Kallikrein 13: a new player in coronaviral infections","author":"Milewska","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2020.110891_bib0255","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1152\/ajplung.00498.2016","article-title":"Attenuation of pulmonary ACE 2 activity impairs inactivation of des-arg9 bradykinin\/BKB1R axis and facilitates LPS induced neutrophil infiltration","volume":"314","author":"Sodhi","year":"2018","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0260","first-page":"2020040023","article-title":"Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach","author":"van de Veerdonk","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.biopha.2020.110891_bib0265","article-title":"Peptide mimicrying between SARS coronavirus spike protein and human proteins reacts with SARS patient serum","author":"Hwa","year":"2008","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.biopha.2020.110891_bib0270","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110891_bib0275","article-title":"The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding","author":"Mycroft-West","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2020.110891_bib0280","doi-asserted-by":"crossref","first-page":"198073","DOI":"10.1016\/j.virusres.2020.198073","article-title":"Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection","volume":"286","author":"Li","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0285","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","article-title":"Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19","volume":"92","author":"Khalili","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0290","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110891_bib0295","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0305","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.1016\/j.tmaid.2020.101735","article-title":"Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review","volume":"35","author":"Hashem","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110891_bib0310","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijbiomac.2018.03.102","article-title":"Chloroquine diphosphate bearing dextran nanoparticles augmented drug delivery and overwhelmed drug resistance in Plasmodium falciparum parasites","volume":"114","author":"Kashyap","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2020.110891_bib0315","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4081\/monaldi.2020.1290","article-title":"Chloroquine in COVID-19: the evidence","volume":"90","author":"Gupta","year":"2020","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.biopha.2020.110891_bib0320","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.1016\/j.tmaid.2020.101735","article-title":"Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review","volume":"35","author":"Hashem","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110891_bib0325","doi-asserted-by":"crossref","first-page":"m1432","DOI":"10.1136\/bmj.m1432","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2020.110891_bib0330","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2020.110891_bib0335","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2020.110891_bib0340","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"367","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2020.110891_bib0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01409","article-title":"Beyond anti-viral effects of chloroquine\/hydroxychloroquine","author":"Gies","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2020.110891_bib0350","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0162-3109(85)90036-0","article-title":"Effects of chloroquine on the serum complement system","volume":"10","author":"Chakrabarty","year":"1985","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.biopha.2020.110891_bib0355","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/JVI.80.5.2326-2336.2006","article-title":"Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M","volume":"80","author":"Oostra","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0360","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12840","article-title":"Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects","author":"Humeniuk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2020.110891_bib0365","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 -Preliminary report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0370","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with Sever Covid-19","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0375","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110891_bib0380","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with Severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0385","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110891_bib0390","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110891_bib0395","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijcard.2020.05.036","article-title":"Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin","volume":"316","author":"Cipriani","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0400","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110891_bib0405","doi-asserted-by":"crossref","first-page":"e017144","DOI":"10.1161\/JAHA.120.017144","article-title":"Experience with hydroxychloroquine and azithromycin in the COVID-19 pandemic: implications for qt interval monitoring","volume":"9","author":"Ramireddy","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2020.110891_bib0410","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","article-title":"Off-label\" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers","volume":"75","author":"G\u00e9rard","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.biopha.2020.110891_bib0415","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0420","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","author":"Yu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.biopha.2020.110891_bib0425","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","article-title":"QT interval prolongation and Torsade De Pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin","volume":"17","author":"Chorin","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.biopha.2020.110891_bib0430","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2020.110891_bib0435","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0440","doi-asserted-by":"crossref","first-page":"e008662","DOI":"10.1161\/CIRCEP.120.008662","article-title":"The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-COV-2 infection","volume":"13","author":"Saleh","year":"2020","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0445","first-page":"e008662","article-title":"Efficacy and safety of hydroxychloroquine combined with azithromycin in treatment of patients with refractory common coronavirus disease-19(COVID-19)","volume":"13","author":"Wu","year":"2020","journal-title":"Acad. J. Second Mil. Med. Univ."},{"key":"10.1016\/j.biopha.2020.110891_bib0450","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.biopha.2020.110891_bib0455","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.biopha.2020.110891_bib0460","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","article-title":"Treating COVID-19 with chloroquine","volume":"12","author":"Huang","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2020.110891_bib0465","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110891_bib0470","first-page":"36","article-title":"Thirteen cases of COVID patients treated by the combination of lopinavir\/ritonavir tablets, atomized interferon \u03b1-2b and thymosin \u03b11","volume":"5","author":"Zheng","year":"2020","journal-title":"Clinical Res. Practice"},{"key":"10.1016\/j.biopha.2020.110891_bib0475","first-page":"E012","article-title":"Real-world efficacy and safety of lopinavir\/ritonavir and arbidol in treating with COVID-19 : an observational cohort study","volume":"59","author":"Wen","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.biopha.2020.110891_bib0480","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0485","doi-asserted-by":"crossref","first-page":"2000799","DOI":"10.1183\/13993003.00799-2020","article-title":"Factors associated with prolonged viral shedding and impact of Lopinavir\/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection","volume":"56","author":"Yan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110891_bib0490","first-page":"154","article-title":"Lianhua Qingwen capsule and interferon-\u03b1 combined with lopinavir\/ritonavir for the treatment of 30 COVID-19 patients","volume":"45","author":"Wang","year":"2020","journal-title":"J. Bengbu Med. Coll."},{"key":"10.1016\/j.biopha.2020.110891_bib0495","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2020.110891_bib0500","article-title":"Safety Analysis of lopinavir\/ritonavir tablets in 40 hospitalized patients with Coronavirus Disease 2019","author":"Liang","year":"2020","journal-title":"Chin. J. Hosp. Pharm"},{"key":"10.1016\/j.biopha.2020.110891_bib0505","first-page":"485","article-title":"Analysis of diarrhea associated with lopinavir-ritonavir for COVID-19 and its prevention","volume":"32","author":"Yang","year":"2020","journal-title":"Med. J. West China"},{"key":"10.1016\/j.biopha.2020.110891_bib0510","article-title":"Pharmaceutical care of lopinave\/litonawe in the treatment of critically coronavirus disease 2019","author":"Xu","year":"2020","journal-title":"Chin. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110891_bib0515","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jmii.2020.03.032","article-title":"Lopinavir\/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan","volume":"53","author":"Cheng","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.biopha.2020.110891_bib0520","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.biopha.2020.110891_bib0525","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.micinf.2020.05.012","article-title":"Arbidol\/IFN-\u03b12b therapy for patients with Corona Virus Disease 2019: a retrospective multicenter cohort study","volume":"22","author":"Xu","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.biopha.2020.110891_bib0530","article-title":"Clinical observation of arbidol combined with diammonium glycyrrhizinate in the treatment of COVID-19","author":"Xi","year":"2020","journal-title":"Chin. J. Hosp. Pharm"},{"key":"10.1016\/j.biopha.2020.110891_bib0535","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2020.110891_bib0540","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11596-020-2203-3","article-title":"Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission-A preliminary report of a retrospective cohort Study","volume":"40","author":"Zhang","year":"2020","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.biopha.2020.110891_bib0545","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2020.110891_bib0550","article-title":"Clinical study on combined scheme of Lianhuaqingwen Capsules and abidole in the treatment for coranavirus disease 2019","author":"Liu","year":"2020","journal-title":"Guangdong Med. J."},{"key":"10.1016\/j.biopha.2020.110891_bib0555","first-page":"26","article-title":"Retrospective clinical study of efficacy and safety of arbidol hydrochloride in the treatment of corona virus disease 2019 with common type","volume":"18","author":"Zang","year":"2020","journal-title":"Clin. Med. J."},{"key":"10.1016\/j.biopha.2020.110891_bib0560","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110891_bib0565","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0014-4894(92)90135-W","article-title":"Effect of nifedipine treatment on oxidative metabolism of peritoneal macrophages and neutrophils of Plasmodium berghei-infected mice","volume":"74","author":"Kalra","year":"1992","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.biopha.2020.110891_bib0570","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.2042-7158.1993.tb05595.x","article-title":"Effect of nifedipine on calcium status and chemiluminescence response of phagocytes during Plasmodium berghei infection in mice","volume":"45","author":"Kalra","year":"1993","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110891_bib0575","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1699-0463.1993.tb00163.x","article-title":"Altered course of Plasmodium berghei infection by nifedipine treatment","volume":"101","author":"Kalra","year":"1993","journal-title":"APMIS"},{"key":"10.1016\/j.biopha.2020.110891_bib0580","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-009-1060-3","article-title":"Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics","volume":"65","author":"Madan","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110891_bib0585","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/CAD.0b013e32834159b8","article-title":"Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses","volume":"22","author":"Madan","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2020.110891_bib0590","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nano.2012.10.003","article-title":"Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells","volume":"9","author":"Madan","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2020.110891_bib0595","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2174\/138920012803762756","article-title":"Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells","volume":"13","author":"Chandra","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.biopha.2020.110891_bib0600","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/CAD.0b013e32835ec414","article-title":"Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study","volume":"24","author":"Jain","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2020.110891_bib0605","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcis.2014.12.092","article-title":"Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies","volume":"445","author":"Jyoti","year":"2015","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.biopha.2020.110891_bib0610","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.colsurfb.2015.05.022","article-title":"Wheat germ agglutinin anchored chitosan microspheres of reduced brominated derivative of noscapine ameliorated acute inflammation in experimental colitis","volume":"132","author":"Kaur","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2020.110891_bib0615","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1568026616666160530153518","article-title":"Noscapine and its analogs as chemotherapeutic agent: current updates","volume":"17","author":"Tomar","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110891_bib0620","doi-asserted-by":"crossref","first-page":"9106","DOI":"10.1128\/JVI.74.19.9106-9114.2000","article-title":"Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate","volume":"74","author":"Trybala","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0625","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/med.21357","article-title":"The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications","volume":"35","author":"Rida","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2020.110891_bib0630","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110891_bib0635","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21676","article-title":"Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2","author":"Ebrahimi","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0640","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1128\/JVI.01248-09","article-title":"Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63","volume":"84","author":"Glowacka","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0645","first-page":"487","article-title":"The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents","volume":"102","author":"Espana","year":"1983","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.biopha.2020.110891_bib0650","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1016\/j.biomaterials.2009.05.076","article-title":"Moderation of prekallkrein-factor XII interactions in surface activation of coagulation by protein-adsorption competition","volume":"30","author":"Chatterjee","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2020.110891_bib0655","article-title":"Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures","author":"Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2020.110891_bib0660","doi-asserted-by":"crossref","first-page":"e23710","DOI":"10.1371\/journal.pone.0023710","article-title":"Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans","volume":"6","author":"Lang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110891_bib0665","doi-asserted-by":"crossref","first-page":"13221","DOI":"10.1128\/JVI.02078-14","article-title":"Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells","volume":"88","author":"Milewska","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0670","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/BST20170399","article-title":"Subverting the mechanisms of cell death: flavivirus manipulation of host cell responses to infection","volume":"46","author":"Vicenzi","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biopha.2020.110891_bib0675","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/jvi.63.1.52-58.1989","article-title":"Initial interaction of herpes simplex virus with cells is binding to heparan sulfate","volume":"63","author":"WuDunn","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0680","first-page":"640","article-title":"Inhibition of influenza H5N1 invasion by modified heparin derivatives","volume":"6","author":"Skidmore","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0685","first-page":"11313","article-title":"Interaction of HIV-1 Tat protein with heparin","volume":"272","author":"Rusnati","year":"1997","journal-title":"Role of the backbone structure, sulfation, and size, J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110891_bib0690","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/glycob\/8.2.131","article-title":"Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor","volume":"8","author":"Harrop","year":"1998","journal-title":"CD4. Glycobiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0695","article-title":"SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner","author":"Liu","year":"2020","journal-title":"bioRxiv."},{"key":"10.1016\/j.biopha.2020.110891_bib0700","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decrease mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2020.110891_bib0705","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jac\/dkh002","article-title":"Vitamin C and SARS coronavirus","volume":"52","author":"Hemila","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2020.110891_bib0710","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.11825","article-title":"Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the Citris-Ali randomized clinical trial","volume":"322","author":"Fowler","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110891_bib0715","series-title":"Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","author":"Peng","year":"2020"},{"key":"10.1016\/j.biopha.2020.110891_bib0720","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/nu12040988","article-title":"Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths","volume":"12","author":"Grant","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2020.110891_bib0725","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S2213-8587(20)30268-0","article-title":"Vitamin D for COVID-19: a case to answer?","volume":"8","author":"Martineau","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2020.110891_bib0730","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110891_bib0735","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/infdis\/jiw080","article-title":"Prophylaxis with a middle East Respiratory Syndrome Coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infectionm","volume":"213","author":"Houser","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110891_bib0740","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.03.025","article-title":"Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets","volume":"143","author":"van Doremalen","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110891_bib0745","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2020.110891_bib0750","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"De Clercq","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.biopha.2020.110891_bib0755","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijsu.2020.06.029","article-title":"Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence","volume":"80","author":"Wiwanitkit","year":"2020","journal-title":"Int. J. Surg."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220310830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220310830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:09:57Z","timestamp":1792721397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220310830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":151,"alternative-id":["S0753332220310830"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110891","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding the silent walk of COVID-19: Halting its spread using old bullets","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110891"}}